10x Genomics acquires two companies to broaden its product line | Tim Talk | Tim Hunt | PleasantonWeekly.com |

Local Blogs

Tim Talk

By Tim Hunt

E-mail Tim Hunt

About this blog: I am a native of Alameda County, grew up in Pleasanton and currently live in the house I grew up in that is more than 100 years old. I spent 39 years in the daily newspaper business and wrote a column for more than 25 years in add...  (More)

View all posts from Tim Hunt

10x Genomics acquires two companies to broaden its product line

Uploaded: Oct 13, 2020
Pleasanton can celebrate several life science companies for their rapid growth in a critical sector for people on this earth.

When I interviewed the CEO of one of those firms, Serge Saxanov of 10x Genomics, more than a year ago what struck me is his statement that scientists understood less than 5% of the biology of the human body.

10x is one of those remarkable success stories. It makes the equipment that enables researchers explore the body at a sub-cellular level. Founded in 2012, it went public last year at $39 per share and was valued at $3.6 billion after the initial public offering. In January 2019, it closed its Series D fundraising as the Livermore Valley’s first homegrown unicorn valued at more than $1 billion.

The situation, with COVID-19 driving research, has only improved for 10x Genomics. One year ago, the stock closed at $50 per share. A year later, the stock has soared to $157. That brought its valuation to almost $16.4 billion—quite a one-year run.

The company builds integrated solutions including instruments, consumables and software for analyzing biological systems. Its products are used by 97 of the top 100 global research institutions and 19 of the top 20 global pharmaceutical firms. It has more than 825 issued patents and patent applications in its portfolio.

Last week, 10x announced two acquisitions (the soaring stock price helps) that position it to broaden its services. It is acquiring ReadCoor, Inc., headquartered in Boston, for cash and stock of $350 million. In August it acquired Stockholm-based CartaNA AB for $42 million. Both firms are developing In Situ technologies. The technology gives scientists the ability to measure large numbers of molecules at the sub-cellular resolution. It complements existing 10x Chromium Single Cell and Visium Spatial platforms. This will be the third major technology platform.
“Our goal has always been to anticipate the frontiers of biology and build products that accelerate science in exponential ways. We believe that In Situ approaches will be essential for how biological research and clinical assays will be conducted in the future. After a comprehensive assessment of In Situ efforts worldwide, we are thrilled to welcome ReadCoor and CartaNA to the 10x team,” said Saxonov in a press release. "Both companies have made significant technical advances, which will serve as a powerful foundation for future product development at 10x. We look forward to joining forces to help our customers make amazing new discoveries to advance human health.”
ReadCoor was spun out of George Church’s lab at Harvard University and CartaNA came out of work from Mats Nilsson’s SciLife Lab at Stockholm University. In connection with the acquisitions, George Church and Mats Nilsson will become scientific advisors to 10x Genomics, according to the press release.
The CartaNA transaction has closed, while the ReadCoor acquisition is expected to close later this month.

We need your support now more than ever. Can we count on you?

Comments

 +   1 person likes this
Posted by Kevin, a resident of Castlewood,
on Oct 17, 2020 at 8:21 am

Kevin is a registered user.

Companies like 10x, Veeva, Roche, Workday contribute to the great city of Pleasanton.


Follow this blogger.
Sign up to be notified of new posts by this blogger.

Email:

SUBMIT

Post a comment

In order to encourage respectful and thoughtful discussion, commenting on stories is available to those who are registered users. If you are already a registered user and the commenting form is not below, you need to log in. If you are not registered, you can do so here.

Please make sure your comments are truthful, on-topic and do not disrespect another poster. Don't be snarky or belittling. All postings are subject to our TERMS OF USE, and may be deleted if deemed inappropriate by our staff.

See our announcement about requiring registration for commenting.


Get important election coverage sent straight to your inbox daily.

Setting the record straight on NDB, Inc. of Pleasanton
By Tim Hunt | 1 comment | 834 views

Premarital and Couples: I’m not getting what I need. How can I get him/her to change?
By Chandrama Anderson | 0 comments | 580 views

Assessing Online Learning—Before, During and After COVID-19
By Elizabeth LaScala | 1 comment | 488 views